Otonomy OTIC shares are trading higher on Tuesday.
The company reported results from its Phase 1/2 clinical trial of OTO-313 in patients with Tinnitus demonstrated a higher proportion of responders than placebo.
Otonomy is a biopharmaceutical company, focused on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients.
The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of U.S.
Otonomy shares were trading up 14.15% at $3.63 on Tuesday. The stock has a 52-week high of $4.18 and a 52-week low of $1.53.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
